Aceso Life Science Announces Update on Joint Venture Formation with Jiangsu Lettall

Reuters
05-13
Aceso Life Science Announces Update on Joint Venture Formation with Jiangsu Lettall

Aceso Life Science Group Ltd. announced an update regarding the formation of a joint venture with Jiangsu Lettall. Initially disclosed on 30 March 2025, the joint venture agreement entails HTICI, a subsidiary of Aceso, and Jiangsu Lettall owning 75% and 25% of the JV Company, respectively. Recently, HTICI completed a share placement, leading to a dilution of Aceso's holding in HTICI. Consequently, HTICI's results and financial position will no longer be consolidated into Aceso's financial statements but will be accounted for separately as an associate. This update affects the company's reporting obligations regarding the joint venture agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aceso Life Science Group Ltd. published the original content used to generate this news brief on May 13, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10